Please login to the form below

Not currently logged in
Email:
Password:

GSK to cut 3,000 jobs

GlaxoSmithKline is to announce more than 3,000 job cuts at its European and US operations as a result of a shift in focus to emerging markets

It is reported that GlaxoSmithKline is to announce more than 3,000 job cuts at its European and US operations as a result of a shift in focus from stagnant Western markets to China in particular, and emerging markets in Asia and Latin America.

GSK aims to reduce £1.7bn in annual costs by the end of next year and re-focus efforts on research and development. Demand for the company's Pandremix vaccine against H1N1 has been lower than anticipated and sales of GSK's H1N1 drug Relenza have also fallen short.

Analysts have said that the group is too reliant on aging patents – the company has been hit most recently by generic versions of its herpes treatment Valtrex after expiry of its US patent.

1st February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...

Infographics